Screening for retinopathy of prematurity

O’Keefe, Michael; Kirwan, Caitriona

doi:10.1016/j.earlhumdev.2007.11.006

Cited by 22 publications

(20 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Laser photocoagulation is performed to destruct the non-vascularized retina, decreasing the release of angiogenic factors and subsequent neovascular complications (16,17) . Destruction of non-vascularized retina in the treatment of ROP was initially achieved with cryotherapy (6) .…”

Section: Discussionmentioning

confidence: 99%

“…Destruction of non-vascularized retina in the treatment of ROP was initially achieved with cryotherapy (6) . Later, LT proved as effective as cryotherapy in the treatment of ROP, inducing less pressure and trauma to the eye, being more effective for zone-1 and -2 diseases than cryotherapy using laser (17) . Low BW and small GA are known to be risk factors for the development of ROP (18) .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Treatment success of laser therapy for retinopathy of prematurity in referred and non-referred patients

Kara¹,

Petriçli²,

Hekimoğlu³

et al. 2016

Arquivos Brasileiros De Oftalmologia

View full text Add to dashboard Cite

Purpose: Comparison of laser therapy (LT) outcomes in patients with retinopathy of prematurity (ROP) followed up in our clinic and referred from other centers. Methods: Medical records of 1,856 ROP patients were retrospectively evaluated, and a total of 128 patients who underwent LT were included in the study. The study population was divided into the following two groups: patients who were followed up and treated in our clinic (group 1, N=45) and patients who were referred to our clinic from other centers (group 2, N=83). Data regarding birth weight, sex, gestational age, postnatal treatment time, disease localization, and stage were analyzed and compared between the two groups. Treatment success was defined by anatomic success 6 months after treatment. Results: Patients in the referred group presented with a more advanced disease (p<0.01), a lower treatment success rate (p=0.01), and a longer time interval between diagnosis and LT (p=0.04). Conclusions:The treatment success rate of ROP was significantly lower in referred patients because of the potential delay in LT and more advanced disease at the time of treatment initiation.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Treatment success of laser therapy for retinopathy of prematurity in referred and non-referred patients

Kara¹,

Petriçli²,

Hekimoğlu³

et al. 2016

Arquivos Brasileiros De Oftalmologia

View full text Add to dashboard Cite

show abstract

“…7,8 The rationale for ROP treatment by laser photocoagulation is to destroy the non-vascularized retina to remove the source of the angiogenic factors, thus interrupting the pathogenic mechanism of the vasoproliferation and subsequent retinal detachment. 4,9 This was achieved for the first time in 1988 by cryotherapy, which proved its efficacy in preventing blindness caused by ROP. 5 In 1994, the Laser ROP study group demonstrated that laser photocoagulation of the retina is as effective as cryotherapy in ROP and has the advantage of causing less severe side effects.…”

Section: Rationale Of the Laser Treatment For Ropmentioning

confidence: 99%

“…[4][5][6] Threshold ROP includes stage 3 (red, vascularized ridge at the limit between the vascularized and non-vascularized retina) with "plus" in zone I or II, extended on more than 5 contiguous or 8 cumulative clock hours. 5,6 Pre-threshold ROP includes less than threshold disease in zone I, stage 2 "plus" disease in zone II, stage 3 without "plus" disease in zone II, and stage 3 "plus" disease less extended than for threshold disease.…”

Section: Rop Classificationmentioning

confidence: 99%

Diode Laser Photocoagulation for Retinopathy of Prematurity: Outcomes After 7 Years of Treatment

Nicoară¹,

Cristian²,

Irimescu³

et al. 2014

J Pediatr Ophthalmol Strabismus

View full text Add to dashboard Cite

Purpose: This study aimed to evaluate the outcome of transpupillary diode laser photocoagulation for retinopathy of prematurity (ROP) at one institution in Romania.Methods: This retrospective case series included all infants who received indirect diode laser photocoagulation for ROP between January 1, 2006, and December 31, 2012. Results:The 160 eyes of 83 infants were classified into two categories: 136 eyes (85%) with classic disease (stage III ROP in zones 1 or 2) and 24 eyes (15%) with aggressive posterior ROP (AP-ROP). ROP regressed in 141 eyes (88.12%). The success rate was significantly better in the classic ROP group (94.11%) compared to the AP-ROP group (54.16%) (P < .001). Conclusions:The ROP regression rate after the laser treatment was 88% in this series.

show abstract

“…Posteriormente, en una segunda fase proliferativa o tardía, se produce un nuevo estímulo pro-angiogénico deficiente que lleva a formación de neovasos y vascularización anormal, alta producción de radicales libres y generación de gran estrés oxidativo (6, 7); todo lo cual puede traccionar y desprender la retina y conducir a ceguera (8,9). El VEGF por tanto juega un papel importante en la patogénesis de la enfermedad (5).…”

Section: Introductionunclassified

Terapia anti-angiogénica con ranibizumab en el tratamiento de retinopatía de la prematuridad

Zuluaga-Gómez

Montoya-López

Donado-Gómez

2018

iatreia

View full text Add to dashboard Cite

RESUMENObjetivo: describir los desenlaces luego de la aplicación de terapia antiangiogénica intraví-trea con Ranibizumab en pacientes con retinopatía de la prematuridad (ROP), tratados inicialmente con termoterapia transpupilar láser sin regresión de la enfermedad.Métodos: cohorte histórica en Clínica Universitaria Bolivariana (CUB) durante 2008-2015. Evaluación de pacientes prematuros con retinopatía agresiva posterior y enfermedad umbral que recibieron termoterapia transpupilar láser como tratamiento inicial. Debido a que continuaba el proceso de neovascularización, se indicó terapia antiangiogénica intravítrea con ranibizumb. El desenlace primario fue la resolución de la neovascularización (NV) y la ausencia de recurrencia. Los desenlaces secundarios fueron agudeza visual y complicaciones oculares y sistémicas.Resultados: ocho ojos de 4 pacientes fueron incluidos. Se encontró resolución de la neovascularización en 6 de los 8 ojos, densidad de incidencia 48 x 100 personas año, IC 95 % = 17,6 -100 con una mediana de seguimiento de 23.5 meses, rango 13-90 meses. No se encontraron complicaciones oculares ni sistémicas.Conclusión: esta pequeña cohorte sugiere que la inyección intravitrea de ranibizumab para ROP, en casos que inicialmente se trataron con termoterapia transpupilar con láser y no se resolvió la retinopatía, ayudaría como complemento para una evolución favorable.

show abstract

Screening for retinopathy of prematurity

Cited by 22 publications

References 15 publications

Treatment success of laser therapy for retinopathy of prematurity in referred and non-referred patients

Treatment success of laser therapy for retinopathy of prematurity in referred and non-referred patients

Diode Laser Photocoagulation for Retinopathy of Prematurity: Outcomes After 7 Years of Treatment

Terapia anti-angiogénica con ranibizumab en el tratamiento de retinopatía de la prematuridad

Contact Info

Product

Resources

About